Status:
RECRUITING
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Lead Sponsor:
Miltenyi Biomedicine GmbH
Conditions:
Melanoma Stage III
B-cell Non Hodgkin Lymphoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
Detailed Description
The focus in this trial is on the occurrence of any late adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI), i.e. relap...
Eligibility Criteria
Inclusion
- Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
- Patient has provided informed consent prior to enrollment.
Exclusion
- No exclusion criteria
Key Trial Info
Start Date :
May 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2040
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06508775
Start Date
May 5 2024
End Date
December 31 2040
Last Update
November 26 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin
Berlin, Germany, 13353
2
Universitätsklinikum Köln
Cologne, Germany, 50937
3
Uniklinikum Erlangen
Erlangen, Germany, 91054
4
Universitätsmedizin Göttingen
Göttingen, Germany, 37075